SLC5A2 and hydrops fetalis: The influence of SGLT2 inhibitors on NT-proBNP concentrations in HF studies is variable among different cohorts, indicating a 13% substantially decreased NT-proBNP concentration after 52 weeks compared with placebo in patients with HF.